Get the Stockscreener App
1.45
12.65%
-0.21
Pre-market:
1.51
0.06
+4.14%
Rani Therapeutics Holdings Inc stock is traded at $1.45, with a volume of 6.07M.
It is down -12.65% in the last 24 hours and up +195.92% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$1.66
Open:
$1.61
24h Volume:
6.07M
Relative Volume:
0.43
Market Cap:
$68.29M
Revenue:
$1.20M
Net Income/Loss:
$-52.41M
P/E Ratio:
-1.5934
EPS:
-0.91
Net Cash Flow:
$-31.25M
1W Performance:
-30.62%
1M Performance:
+195.92%
6M Performance:
+30.63%
1Y Performance:
-37.50%
1-Day Range:
$1.42
$1.64
1-Week Range:
$1.42
$2.18
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.45 | 79.51M | 1.20M | -52.41M | -31.25M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.89 | 106.97B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.04 | 68.62B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.56 | 63.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
820.36 | 50.61B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.22 | 35.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Will Rani Therapeutics Holdings Inc. stock reach all time highs in 2025CEO Change & Daily Stock Trend Reports - newser.com
Can Rani Therapeutics Holdings Inc. stock maintain growth trajectoryTrend Reversal & Reliable Entry Point Alerts - newser.com
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - The Manila Times
Short interest data insights for Rani Therapeutics Holdings Inc.Stop Loss & Intraday High Probability Setup Alerts - newser.com
Multi asset correlation models including Rani Therapeutics Holdings Inc.Market Growth Review & Weekly Market Pulse Alerts - newser.com
Can momentum traders help lift Rani Therapeutics Holdings Inc.Earnings Performance Report & Weekly Sector Rotation Insights - newser.com
Rani Therapeutics Holdings (RANI) Price Target Increased by 20.00% to 10.71 - Nasdaq
Is Rani Therapeutics Holdings Inc. stock supported by innovation pipelineOptions Play & AI Powered Market Entry Strategies - newser.com
Is Rani Therapeutics Holdings Inc. stock a buy for dividend growth2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Rani Therapeutics (NASDAQ:RANI) Director Mir Imran Buys 2,083,334 Shares - MarketBeat
Rani Therapeutics Hits New 52-Week High of $3.87, Marking Major Milestone - Markets Mojo
Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Israel Englander, Ken Griffin, Michael Burry, Warren Buffett, ExodusPoint Capital, Rani Therapeutics Holdings Inc (RANI), Coca-Cola Co (KO), and More - Insider Monkey
Institutional scanner results for Rani Therapeutics Holdings Inc.Weekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Rani Therapeutics Holdings Insider Bought Shares Worth $1,260,417, According to a Recent SEC Filing - MarketScreener
Will Rani Therapeutics Holdings Inc. bounce back from current supportMarket Activity Report & Weekly Breakout Stock Alerts - newser.com
How to integrate Rani Therapeutics Holdings Inc. into portfolio analysis tools2025 Macro Impact & Daily Volume Surge Signals - newser.com
Rani Therapeutics director Imran Mir a buys $1.26 million in stock - Investing.com Philippines
Technical analysis overview for Rani Therapeutics Holdings Inc. stockInsider Buying & Verified Entry Point Detection - newser.com
Rani Therapeutics director Imran Mir a buys $1.26 million in stock By Investing.com - Investing.com South Africa
Rani Therapeutics Launches Phase 1 Study for Obesity Treatment RT-114 - TipRanks
Rani Therapeutics appoints new directors and closes private placement By Investing.com - Investing.com Nigeria
Rani Therapeutics appoints new directors and closes private placement - Investing.com
Rani Therapeutics Announces Board Changes - TradingView
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):